1. Home
  2. NWS vs BBIO Comparison

NWS vs BBIO Comparison

Compare NWS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo News Corporation Class B

NWS

News Corporation Class B

HOLD

Current Price

$25.80

Market Cap

17.0B

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$78.08

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWS
BBIO
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
15.3B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NWS
BBIO
Price
$25.80
$78.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
21
Target Price
$37.94
$78.81
AVG Volume (30 Days)
1.6M
3.0M
Earning Date
02-05-2026
02-20-2026
Dividend Yield
0.75%
N/A
EPS Growth
178.51
N/A
EPS
2.02
N/A
Revenue
$8,624,000,000.00
$353,780,000.00
Revenue This Year
$5.12
$129.08
Revenue Next Year
$3.39
$79.33
P/E Ratio
$11.75
N/A
Revenue Growth
2.42
62.46
52 Week Low
$25.57
$28.33
52 Week High
$35.58
$81.33

Technical Indicators

Market Signals
Indicator
NWS
BBIO
Relative Strength Index (RSI) 28.69 56.05
Support Level $25.57 $70.09
Resistance Level $27.41 $72.98
Average True Range (ATR) 0.91 4.04
MACD -0.46 -0.24
Stochastic Oscillator 3.34 70.43

Price Performance

Historical Comparison
NWS
BBIO

About NWS News Corporation Class B

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: